GH Research Archives

Psychedelics News

GH Research

Industry

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

Industry

4 Oct 2023

GH Research: Updates on Clinical Development Programs

5-MEO-DMT developer GH Research has provided an update on its main clinical programs....

By Microdose NewsDesk

Finance

26 Aug 2023

GH Research Reports Q2 2023 Financial Results and Business Update

GH Research has reported its second quarter 2023 financial results, with updates on trials and cash on hand....

By Microdose NewsDesk

Finance

12 May 2023

GH Research Reports First Quarter 2023 Financial Results and Business Highlights

GH Research has reported financial results for the first quarter ended March 31, 2023 and provided business highlights....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

23 Sep 2022

GH Research Presents Trial Findings at ICPR Conference

As a public service, we're sharing the presentation the company released this week....

By Microdose NewsDesk

Don’t Miss

29 Aug 2022

News You Might Have Missed: Aug 29th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed....

By Microdose NewsDesk

Industry

24 Aug 2022

A Look at GH Research’s Financial and Business Results

GH Research owns the title of the most low-key player in the psychedelic medicine space....

By Jason Najum

Industry

17 Jun 2022

Top Clinical Trials in 2022 (Part 2)

The success or failure of the sector’s advanced clinical trials will dictate the future of the industry....

By Jason Najum

Industry

9 Dec 2021

GH Research Update: Financials, Business Update, and Trial Results

Now we have news of $280 million in cash on hand, and successful outcomes in a Phase 2 clinical trial using 5-MeO-DMT for treatment-resistant depression....

By Jason Najum

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result